D. Samba Reddy, Ph.D., R.Ph.
Department of Neuroscience and Experimental Therapeutics
Interdisciplinary Program in Neuroscience (TAMU/TAMHSC)
8447 State Highway 47Bryan, Texas 77807-3260
Phone: (979) 436-0324
Ph.D., Pharmacology, Panjab University Chandigarh (1998)
R.Ph, Pharmacy, Texas State BOP, Austin, Texas.
Postdoctoral Fellow, National Institutes of Health, Bethesda, Maryland.
Professional HonorsChartered Member, NIH Study Section CNNT - Clinical Neuroplasiticity and Neurotransmitters
Editor-in-Chief, International Journal of Pharmaceutical Sciences and Nanotechnology
Review Editor, Frontiers in Aging Neuroscience
Delegate Member, The United States Pharmacopoeia (USP)
Registered Pharmacy Practitioner, Texas, United States
Epilepsy, Neurosteroids and New Drug Development
Reddy’s major research goals are to understand the molecular pathophysiology and develop translational novel therapeutic strategies for epilepsy, with an emphasis on endogenous neurosteroids and GABA inhibition. Neurosteroids are steroids synthesized locally within the brain that rapidly change neural excitability by non-genomic mechanisms, principally via postsynaptic GABAA receptors that play critical role in epilepsy. Current work in his lab is focused on uncovering molecular mechanisms of neurosteroids in epilepsy and brain disorders, and testing the efficacy of mechanism-based therapeutic strategies for epilepsy and epileptogenesis. Reddy lab is utilizing multidisciplinary approaches such as pharmacological, molecular, electrophysiological (patch-clamp), mass spectrometry, and transgenic mouse models in research projects.
Epilepsy and seizure disorders affect about 3 million people in the United States and 50 million people worldwide. Despite the availability of several antiepileptic drugs, about one-third of people with epilepsy show seizures that do not respond to even the best available treatment. Presently, there is no cure for epilepsy. Reddy’s lab is testing the efficacy of novel drugs and subunit-preferring agents for treatment or prevention of seizure disorders such as catamenial epilepsy, temporal lobe epilepsy, and status epilepticus. Catamenial epilepsy is a menstrual cycle-related seizure disorder characterized by an increase in seizures around menstruation. Presently, there is no specific, FDA-approved drug therapy for catamenial epilepsy, which affects about 70% of women with epilepsy. Because progesterone plays a vital role in women with epilepsy, his lab is uncovering the molecular mechanism of progesterone actions in the brain. Progesterone regulation of the GABA-A receptor plasticity is being explored as a novel paradigm relevant to catamenial epilepsy. Temporal lobe epilepsy, a chronic condition characterized by recurrent seizures arising from temporal lobes such as the hippocampus, is often drug resistant and novel approaches are being explored in Reddy’s lab to treat or prevent this devastating seizure disorder. Status epilepticus is a neurological emergency characterized by a prolonged, continuous seizure activity with significant mortality and morbidity. Novel therapies are desperately needed for rapid and effective treatment of status epilepticus. Reddy’s lab is translating recent findings into therapy development using mechanism-based strategy that promote tonic inhibition.
He is a faculty member in TAMU Institute of Neuroscience and a member of the graduate faculty in the Texas A&M University.
- Reddy DS (2013). Role of hormones and neurosteroids in epileptogenesis. Frontiers in Cellular Neuroscience 7(115): 1-20.
- Wu X, Gangisetty O, Carver CM and Reddy DS. Estrous cycle-regulation of extrasynaptic δ-containing GABA-A receptor-mediated tonic inhibition and limbic epileptogenesis. J Pharmacol Exp Therap 2013, 346:146-160.
- Reddy DS(2013). The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Reviews of Clinical Pharmacology 6(3):271-288.
- Reddy DS (2013). Neuroendocrine aspects of catamenial epilepsy. Hormones & Behavior 63: 254–266.
- Reddy DS and Ramanathan G (2012). Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Epilepsy & Behavior 25:92-97.
- Reddy DS (2012). Novel new drug approvals in 2011: A succinct analysis of drug discovery trends in the United States. Int J Pharm Sci Nanotech. 5: 1661-1665.
- Reddy DS, Gould J, and Gangisetty O (2012). A mouse kindling model of perimenstrual catamenial epilepsy. J Pharmacol Exp Therap 341:784-793.
- Reddy DS. Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Frontiers in Neuroendocrinology 2011 (vol 2); article 38, pp 1-11.
- Reddy DS (author). Pharmacy Quiz. 2nd Edition. PBS Publishers, Hyderabad 2012, pages 1-1150. **Major review book for pharmacy graduate and board exams**
- Wu X and Reddy DS. Integrins as receptor targets for neurological disorders. Pharmacology & Therapeutics 2012, 134:68-81.
- Reddy DS and Mohan A. Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. Journal of Neuroscience 2011;31 650-658.
- Pack A, Reddy DS, Duncan S and Herzog A. Neuroendocrinological aspects of epilepsy: Important issues and trends in future research. Epilepsy & Behavior 2011, 22:94-102.
- Reddy DS, Gangisetty O. and Briyal S. Disease-modifying activity of progesterone in the hipocampus kindling model of epileptogenesis. Neuropharmacology 2010, 59:573-581.
- Reddy DS. Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Progress in Brain Research 2010, 186: 113-137.
- Gangisetty O. and Reddy DS. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of PR-independent Egr3 pathway. Neuroscience 2010, 170: 865-880.
- Reddy DS and Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABA-A receptors. J Pharmacol Exp Therap 2010, 334:1031-1041.
- Reddy DS and Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Research 2010, 89:254-260.
- Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010, 3(2):183-192.
- Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Research 2009, 85 (1): 1-30.
- Gangisetty O and Reddy DS. The optimization of TaqMan real-time RT-PCR assay for transcriptional profiling of GABA-A receptor subunit plasticity. Journal of Neuroscience Methods 2009, 181(1):58-66.
- Reddy DS and Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6(2):392-401.
- Reddy DS. Mass spectrometric quantification and physiological-pharmacological activity of androgenic neurosteroids. Neurochemistry International 2008; 52(4-5):541-553.
- Zeng Y-C and Reddy DS. Differential anesthetic activity of ketamine and the GABAergic neurosteroid allopregnanolone in mice lacking progesterone receptor A and B subtypes.Methods Find Exp Clin Pharmacol 2007; 29(10):659-64.
- Rao MV, Hattiangady B, Reddy DS and Shetty AK. Hippocampal neurodegeneration, spontaneous seizures and mossy fiber sprouting in F344 rat model of temporal lobe epilepsy. Journal of Neuroscience Research 2006, 83(6):1088-105.
- Reddy DS. Perimenstrual catamenial epilepsy. Women’s Health 2007 3(2): 195-206.
- Reddy DS. Physiological role of adrenal deoxycorticosterone-derived neuroactive steroids in stress-sensitive conditions. Neuroscience 2006; 138:911-920.
- Reddy DS, Chien B, and Ramu K. A high-performance liquid chromatography-tandem mass spectrometry assay of the androgenic neurosteroid 3α-androstanediol in plasma. Steroids 2005, 70:879-885.
Reddy Lab Personnel
- Dr. D. Samba Reddy - Principal Investigator
- Dr. Xin Wu - Research Assistant Professor
- Dr. Ramkumar Kuruba - Postdoctoral Fellow
- Chase Carver - Graduate student
- Bryan Clossan - Graduate student
- Jonathan Brewer - UG student
- Ryan Ceiker-Research Technician
- Divya Raju, UG student
Lab Phone: (979) 436-0370